Municipal Health Service Hart voor Brabant, 's-Hertogenbosch, Netherlands.
Microvida, Elisabeth-Tweesteden Hospital, Tilburg, Netherlands.
J Clin Virol. 2022 Jun;150-151:105131. doi: 10.1016/j.jcv.2022.105131. Epub 2022 Mar 14.
Quantitative results of SARS-CoV-2 testing reported as viral load copies/mL can provide valuable information, but are rarely used in practice. We analyze whether viral load in the upper respiratory tract is correlated with transmission and disease course and how this information can be used in practice.
Municipal Health Service (MHS) and clinical patients ≥18 years tested positive for SARS-CoV-2 with RT-PCR between June 1 and September 25, 2020 were included. Transmission was defined as an index having at least one contact tested positive. Test delay was defined as the time between symptom onset and SARS-CoV-2 testing.
683 patients were included (656 MHS and 27 clinical patients). The viral load was considerably lower among clinical patients compared to MHS patients: median log copies/mL 2.51 (IQR -1.52 - 6.46) vs 4.92 (IQR -0.54 - 8.26), p < 0.0001. However, the test delay was higher for clinical patients (median 7 [IQR 2 - 19] vs 3 [IQR 0 - 26] days, p < 0.0001). SARS-CoV-2 transmitters showed much higher viral loads than non-transmitters (log copies/mL 5.23 [IQR -0.52 - 8.26] vs 4.65 [IQR -0.72 - 8.00], p < 0.0001), but not for those with a test delay > 7 days. Higher viral loads were significantly correlated with older age and with more (severe) COVID-19 related symptoms.
Indexes that transmitted SARS-CoV-2 had more than three times higher viral loads than non-transmitters. Viral load information can be useful during source and contact tracing to prioritize indexes with highest risk of transmission, taking into account the test delay.
以病毒载量拷贝数/ml 报告的 SARS-CoV-2 检测定量结果可提供有价值的信息,但在实践中很少使用。我们分析了上呼吸道病毒载量与传播和疾病过程的相关性,以及如何在实践中使用这些信息。
纳入 2020 年 6 月 1 日至 9 月 25 日期间经 RT-PCR 检测呈 SARS-CoV-2 阳性的市级卫生服务机构(MHS)和临床患者(≥18 岁)。传播定义为指数至少有一个接触者检测呈阳性。检测延迟定义为症状出现与 SARS-CoV-2 检测之间的时间。
共纳入 683 例患者(MHS 患者 656 例,临床患者 27 例)。临床患者的病毒载量明显低于 MHS 患者:中位数对数拷贝/ml 2.51(IQR -1.52 - 6.46)比 4.92(IQR -0.54 - 8.26),p<0.0001。然而,临床患者的检测延迟较高(中位数 7[IQR 2 - 19]天比 3[IQR 0 - 26]天,p<0.0001)。SARS-CoV-2 传播者的病毒载量明显高于非传播者(对数拷贝/ml 5.23[IQR -0.52 - 8.26]比 4.65[IQR -0.72 - 8.00],p<0.0001),但检测延迟>7 天者则不然。较高的病毒载量与年龄较大以及更多(严重)COVID-19 相关症状显著相关。
传播 SARS-CoV-2 的指标病毒载量比非传播者高 3 倍以上。在进行传染源和接触者追踪时,病毒载量信息可用于确定传播风险最高的指标,同时考虑到检测延迟。